Zenas BioPharma Director Increases Stake with $70K Stock Purchase

Insider buying signals confidence in the biotech company's future prospects.

Apr. 2, 2026 at 11:03pm

Got story updates? Submit your updates here. ›

A highly detailed, cinematic close-up of the inner workings and machinery of a complex medical device, conveying the technical sophistication and engineering prowess driving Zenas BioPharma's drug development efforts.An insider's view of the intricate machinery behind Zenas BioPharma's innovative biotech work.Cambridge Today

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Director Hongbo Lu purchased 3,768 shares of the company's stock in a transaction on March 31, 2026. The shares were acquired at an average price of $18.63 per share, for a total transaction value of $70,197.84. This purchase increases Lu's direct ownership stake in Zenas BioPharma to 426,736 shares, representing a 0.89% increase in their holdings.

Why it matters

Insider buying activity is often viewed as a positive signal, indicating that company leadership believes the stock is undervalued and has confidence in the firm's future performance. Zenas BioPharma is a clinical-stage biotech company focused on novel therapies in oncology and infectious diseases, so this purchase suggests the director sees significant upside potential in the company's pipeline and prospects.

The details

The stock purchase was disclosed in a filing with the Securities and Exchange Commission. Following the transaction, Director Hongbo Lu now owns 426,736 shares of Zenas BioPharma, valued at approximately $7.95 million based on the latest closing price. This trade represents a 0.89% increase in Lu's ownership stake in the company.

  • The stock purchase was made on Tuesday, March 31, 2026.
  • Hongbo Lu also purchased 25,985 shares of Zenas BioPharma stock on February 11, 2026 at an average price of $22.50 per share.

The players

Hongbo Lu

Director of Zenas BioPharma, Inc.

Zenas BioPharma, Inc.

A clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases.

Got photos? Submit your photos here. ›

The takeaway

This insider purchase by a Zenas BioPharma director suggests the company's leadership sees significant upside potential in the biotech firm's pipeline and future prospects, despite the stock trading well below its 52-week high. Insider buying activity is often viewed as a positive signal for investors to consider.